A phase 1 study of prasugrel in patients with sickle cell disease: Pharmacokinetics and effects on ex vivo platelet reactivity

British Journal of Clinical Pharmacology

Volumn 75, Issue 6, 2013, Pages 1433-1444

  Jakubowski, Joseph A ^a   Zhou, Chunmei ^a   Small, David S ^a   Winters, Kenneth J ^a   Lachno, D Richard ^a   Frelinger, Andrew L ^b   Howard, Jo ^c   Mant, Timothy G ^d   Jurcevic, Stipo ^e   Payne, Christopher D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine diphosphate; P2Y12 receptor antagonist; Platelet; Prasugrel; Sickle cell

Indexed keywords

PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MUSCULOSKELETAL STIFFNESS; OROPHARYNX PAIN; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SICKLE CELL ANEMIA; THORAX PAIN; THROMBOCYTE AGGREGATION; VOMITING;

ADULT; ANEMIA, SICKLE CELL; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; PIPERAZINES; PLATELET FUNCTION TESTS; PURINERGIC P2 RECEPTOR ANTAGONISTS; THIOPHENES; YOUNG ADULT;

EID: 84878121613     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12042     Document Type: Article

References (35)

1. World Health Organization [Internet]. Genes and human disease 2012. Available at http://www.who.int/genomics/public/geneticdiseases/en/index2.html (last accessed 6 December 2012).
2. Francis RB Jr, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991; 77: 1405-1414.
3. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115: 721-728.
4. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139: 3-13.
5. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997; 129: 507-516.
6. Charneski L, Congdon HB. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am J Health Syst Pharm 2010; 67: 895-900.
7. Stuart MJ, Setty BN. haemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 2001; 20: 27-46.
8. Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol 2004; 76: 126-133.
9. Jakubowski JA, Winters KJ, Naganuma H, Walletin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
10. Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989; 31: 237-241.
11. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F. Platelet activation in patients with sickle cell disease. Br J Haematol 1998; 100: 741-749.
12. Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004; 18: 172-177.
13. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1626-1631.
14. Lee SP, Ataga KI, Zayed M, Manganello JM, Orringer EP, Phillips DR, Parise LV. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 2007; 139: 612-620.
15. Osamo NO, Photiades DP, Famodu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1981; 66: 102-107.
16. Chaplin H Jr, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 1980; 43: 218-221.
17. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984; 15: 199-212.
18. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983; 102: 781-784.
19. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-306.
20. Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984; 72: 61-64.
21. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-142.
22. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60: 635-642.
23. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
24. Jakubowski JA, Zhou C, Egan B, Wells M, Kotob-Yahfoufi M, Sugidachi A, Dahlen JR. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12 antagonism. Platelets 2011; 22: 619-625.
25. Jakubowski JA, Bourguet N, Boulay-Moine D, Sugidachi A, Yamaguchi S, Barragan P, Zhou C, Moulard M. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition. Thromb Haemost 2012; 107: 388-395.
26. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
27. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 169-179.
28. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532.
29. Born GV. Adenosine diphosphate is a mediator of platelet aggregation in vivo: an editorial view. Circulation 1985; 72: 741-746.
30. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007; 5: 45-55.
31. Toma C, Zahr F, Moguilanski D, Grate S, Semaan RW, Lemieux N, Lee JS, Cortese-Hassett A, Mulukutla S, Rao SV, Marroquin OC. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol 2012; 109: 1148-1153.
32. Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
33. Voisin S, Bongard V, Tidjane MA, Lhermusier T, Carrié D, Sié P. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost 2011; 106: 227-229.
34. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
35. Wun T, Soulieres D, Krishnamurti L, Kutlar A, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Winters KJ, Ataga K, Riesmeyer JS. A randomized, double-blind, adaptive phase 2 multi-center study of prasugrel compared to placebo in adults with sickle cell disease [abstract]. 53rd American Society of Hematology Annual Meeting and Exposition, 2011. Abstract 847.